Annual Retained Earnings
-$158.48 M
-$7.63 M-5.06%
December 31, 2023
Summary
- As of February 7, 2025, CANF annual retained earnings is -$158.48 million, with the most recent change of -$7.63 million (-5.06%) on December 31, 2023.
- During the last 3 years, CANF annual retained earnings has fallen by -$33.01 million (-26.31%).
- CANF annual retained earnings is now -161.64% below its all-time high of -$60.57 million, reached on December 31, 2011.
Performance
CANF Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Retained Earnings
-$162.44 M
-$3.96 M-2.50%
June 30, 2024
Summary
- As of February 7, 2025, CANF quarterly retained earnings is -$162.44 million, with the most recent change of -$3.96 million (-2.50%) on June 30, 2024.
- Over the past year, CANF quarterly retained earnings has dropped by -$7.37 million (-4.75%).
- CANF quarterly retained earnings is now -169.27% below its all-time high of -$60.33 million, reached on September 30, 2011.
Performance
CANF Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Retained Earnings Formula
Retained Earnings = Retained Earnings (start of the period) + Net Income − Dividends Paid
CANF Retained Earnings Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -5.1% | -4.8% |
| 3 y3 years | -26.3% | -24.4% |
| 5 y5 years | -57.5% | -54.0% |
CANF Retained Earnings Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -12.7% | at low | -15.5% | at low |
| 5 y | 5-year | -43.7% | at low | -47.3% | at low |
| alltime | all time | -161.6% | at low | -169.3% | at low |
Can-Fite BioPharma Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2024 | - | -$162.44 M(+2.5%) |
| Dec 2023 | -$158.48 M(+5.1%) | -$158.48 M(+1.1%) |
| Sep 2023 | - | -$156.83 M(+1.1%) |
| Jun 2023 | - | -$155.07 M(+1.1%) |
| Mar 2023 | - | -$153.40 M(+1.7%) |
| Dec 2022 | -$150.85 M(+7.2%) | -$150.85 M(+2.0%) |
| Sep 2022 | - | -$147.83 M(+1.7%) |
| Jun 2022 | - | -$145.30 M(+1.5%) |
| Mar 2022 | - | -$143.11 M(+1.7%) |
| Dec 2021 | -$140.67 M(+12.1%) | -$140.67 M(+5.0%) |
| Sep 2021 | - | -$133.97 M(+2.6%) |
| Jun 2021 | - | -$130.57 M(+2.5%) |
| Mar 2021 | - | -$127.35 M(+1.5%) |
| Dec 2020 | -$125.47 M(+13.7%) | -$125.47 M(+3.0%) |
| Sep 2020 | - | -$121.84 M(+2.2%) |
| Jun 2020 | - | -$119.26 M(+8.1%) |
| Dec 2019 | -$110.31 M(+9.6%) | - |
| Dec 2019 | - | -$110.31 M(+1.7%) |
| Sep 2019 | - | -$108.46 M(+2.8%) |
| Jun 2019 | - | -$105.52 M(+3.0%) |
| Mar 2019 | - | -$102.45 M(+1.8%) |
| Dec 2018 | -$100.62 M(+7.4%) | - |
| Dec 2018 | - | -$100.62 M(+3.5%) |
| Sep 2018 | - | -$97.19 M(+0.2%) |
| Jun 2018 | - | -$97.02 M(+2.5%) |
| Mar 2018 | - | -$94.65 M(+1.0%) |
| Dec 2017 | -$93.70 M | - |
| Dec 2017 | - | -$93.70 M(-9.1%) |
| Sep 2017 | - | -$103.04 M(-0.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | -$103.73 M(+6.0%) |
| Mar 2017 | - | -$97.87 M(+7.6%) |
| Dec 2016 | -$90.98 M(+10.0%) | - |
| Dec 2016 | - | -$90.98 M(-0.2%) |
| Sep 2016 | - | -$91.14 M(+5.2%) |
| Jun 2016 | - | -$86.64 M(-0.3%) |
| Mar 2016 | - | -$86.93 M(+5.1%) |
| Dec 2015 | -$82.71 M(+5.9%) | - |
| Dec 2015 | - | -$82.71 M(+0.3%) |
| Sep 2015 | - | -$82.48 M(-0.1%) |
| Jun 2015 | - | -$82.56 M(+6.9%) |
| Mar 2015 | - | -$77.21 M(-1.1%) |
| Dec 2014 | -$78.11 M(-3.0%) | - |
| Dec 2014 | - | -$78.11 M(-3.0%) |
| Sep 2014 | - | -$80.52 M(-5.5%) |
| Jun 2014 | - | -$85.18 M(+4.1%) |
| Mar 2014 | - | -$81.79 M(+1.6%) |
| Dec 2013 | -$80.51 M(+19.7%) | -$80.51 M(+6.6%) |
| Sep 2013 | - | -$75.50 M(+4.1%) |
| Jun 2013 | - | -$72.50 M(+2.4%) |
| Mar 2013 | - | -$70.83 M(+5.3%) |
| Dec 2012 | -$67.28 M(+11.1%) | - |
| Dec 2012 | - | -$67.28 M(+7.6%) |
| Sep 2012 | - | -$62.53 M(+1.9%) |
| Jun 2012 | - | -$61.34 M(-3.2%) |
| Mar 2012 | - | -$63.34 M(+4.6%) |
| Dec 2011 | -$60.57 M | - |
| Dec 2011 | - | -$60.57 M(+0.4%) |
| Sep 2011 | - | -$60.33 M |
FAQ
- What is Can-Fite BioPharma annual retained earnings?
- What is the all time high annual retained earnings for Can-Fite BioPharma?
- What is Can-Fite BioPharma annual retained earnings year-on-year change?
- What is Can-Fite BioPharma quarterly retained earnings?
- What is the all time high quarterly retained earnings for Can-Fite BioPharma?
- What is Can-Fite BioPharma quarterly retained earnings year-on-year change?
What is Can-Fite BioPharma annual retained earnings?
The current annual retained earnings of CANF is -$158.48 M
What is the all time high annual retained earnings for Can-Fite BioPharma?
Can-Fite BioPharma all-time high annual retained earnings is -$60.57 M
What is Can-Fite BioPharma annual retained earnings year-on-year change?
Over the past year, CANF annual retained earnings has changed by -$7.63 M (-5.06%)
What is Can-Fite BioPharma quarterly retained earnings?
The current quarterly retained earnings of CANF is -$162.44 M
What is the all time high quarterly retained earnings for Can-Fite BioPharma?
Can-Fite BioPharma all-time high quarterly retained earnings is -$60.33 M
What is Can-Fite BioPharma quarterly retained earnings year-on-year change?
Over the past year, CANF quarterly retained earnings has changed by -$7.37 M (-4.75%)